Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Gilead Sciences Inc (NASDAQ:GILD)

82.31
Delayed Data
As of Jun 28
 +4.06 / +5.19%
Today’s Change
77.92
Today|||52-Week Range
120.37
-18.66%
Year-to-Date
The FDA Unsurprisingly Approves Gilead's New Hepatitis C Drug. Now What?
Jun 28 / MotleyFool.com - Paid Partner Content
The 3 Most Important Data Releases and FDA Decisions in the Second Half of 2016
Jun 23 / MotleyFool.com - Paid Partner Content
Why Gilead (GILD) Stock Is Gaining Today
Jun 28 / TheStreet.com - Paid Partner Content
Share Buybacks Rise to Record Level in First Quarter
Jun 22 / GuruFocus News - Paid Partner Content
Instant Analysis: Gilead Sciences Wins an Important FDA Approval
Jun 28 / MotleyFool.com - Paid Partner Content
Gilead Downside Is Path of Least Resistance
Jun 22 / TheStreet.com - Paid Partner Content
Why Is Gilead Sciences (GILD) Stock Gaining Today?
Jun 28 / Zacks.com - Paid Partner Content
Biotech Stocks Rally on Medicare Cost-Cutting Stand Down
Jun 22 / TheStreet.com - Paid Partner Content
This Leading Indicator Suggests the Stock Market May Be on the Precipice of Tumbling
Jun 28 / MotleyFool.com - Paid Partner Content
Stock Market News for June 22, 2016
Jun 22 / Zacks.com - Paid Partner Content
Gilead Sciences Bucks Tradition, Takes 'Low Road' on New Hepatitis C Drug Price
Jun 28 / TheStreet.com - Paid Partner Content
Can These Upstarts Knock Gilead Sciences Off Its Perch?
Jun 22 / MotleyFool.com - Paid Partner Content
Regulus Therapeutics Inc. Clinical Hold: Should Investors Be Yellow-Bellied?
Jun 27 / MotleyFool.com - Paid Partner Content
Gilead Presents Favorable Preliminary Bictegravir HIV Data
Jun 21 / Zacks.com - Paid Partner Content
When Will Gilead Sciences, Celgene, and CVS Health Hit $100 Again?
Jun 27 / MotleyFool.com - Paid Partner Content
New Strong Sell Stocks for June 21st
Jun 21 / Zacks.com - Paid Partner Content
The 5 Best Healthcare ETFs
Jun 26 / MotleyFool.com - Paid Partner Content
These 5 Biotech Stocks Are Ridiculously Cheap
Jun 21 / MotleyFool.com - Paid Partner Content
3 Biotech Stocks to Buy Now for the Long Haul
Jun 25 / MotleyFool.com - Paid Partner Content
Why Achillion Pharmaceuticals Is Down Big in 2016
Jun 20 / MotleyFool.com - Paid Partner Content
Can Gilead Sciences Rebound in the Second Half of 2016?
Jun 25 / MotleyFool.com - Paid Partner Content
Gilead Sciences: Where's the Value?
Jun 19 / MotleyFool.com - Paid Partner Content
RBC sees biopharma 'insulated' from Brexit, says buy Celgene for bounceback
Jun 24 / TheStreet.com - Paid Partner Content
The 3 Best Dividend Stocks for Beginning Investors
Jun 19 / MotleyFool.com - Paid Partner Content
Gilead's (GILD) HIV Treatment Odefsey Gains Approval in EU
Jun 24 / Zacks.com - Paid Partner Content
2 Biotech Stocks That Could Raise Their Dividends -- and 1 That Won't
Jun 18 / MotleyFool.com - Paid Partner Content
Gilead (GILD) Weak In Early Morning Trading
Jun 24 / TheStreet.com - Paid Partner Content
3 Reasons Gilead Sciences Is a Buy
Jun 17 / MotleyFool.com - Paid Partner Content
Corporate Share Buybacks Rise to Record Level in First Quarter
Jun 23 / GuruFocus News - Paid Partner Content
New Strong Sell Stocks for June 17th
Jun 17 / Zacks.com - Paid Partner Content
Uh-oh. Is the stock market a bubble again?
Jun 23 / CNNMoney.com
India buyers club: The new way for Americans to buy cheap drugs
Jun 02 / CNNMoney.com